Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Plant Health Care Plc LSE:PHC London Ordinary Share GB00B01JC540 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.60 -3.75% 15.40 15,066 16:29:45
Bid Price Offer Price High Price Low Price Open Price
15.40 16.00 15.40 15.40 15.40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 4.84 -2.42 -0.73 47
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:23 UT 1 15.40 GBX

Plant Health Care (PHC) Latest News

More Plant Health Care News
Plant Health Care Investors    Plant Health Care Takeover Rumours

Plant Health Care (PHC) Discussions and Chat

Plant Health Care (PHC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-18 15:35:2315.4010.15UT
2021-06-18 15:28:0016.0037560.00O
2021-06-18 15:28:0016.0071.12O
2021-06-18 11:09:2616.00101.60O
2021-06-18 11:09:2615.4081.23O
View all Plant Health Care trades in real-time

Plant Health Care (PHC) Top Chat Posts

DateSubject
18/6/2021
09:20
Plant Health Care Daily Update: Plant Health Care Plc is listed in the Chemicals sector of the London Stock Exchange with ticker PHC. The last closing price for Plant Health Care was 16p.
Plant Health Care Plc has a 4 week average price of 15p and a 12 week average price of 14.10p.
The 1 year high share price is 19.30p while the 1 year low share price is currently 7.70p.
There are currently 302,387,482 shares in issue and the average daily traded volume is 93,519 shares. The market capitalisation of Plant Health Care Plc is £46,567,672.23.
06/4/2021
20:28
dlem: 1,029,000 share trade after close!
29/3/2021
20:10
pr4w2b0y: One of the Qs was who are PHC competitors. These co names keep cropping up; Syngenta (Switzerland) Isagro (Italy) BASF GmbH Plant Health Care (US) Arysta LifeScience (US) Nihon Nohyaku Co., Ltd. (Japan) Meiji Seika (Japan) Certis (US) Gowan (US) Futureco Bioscience (Spain) NutriAg (Canada) Eagle Plant Protect Pvt. Ltd. (India) Given the size of these co they are probable JVs & MAs.
27/3/2021
09:28
cerrito: Very much one of the better IMC calls I have listened to with a good presentation and good questions and well worth a listen. Some of the main points for me. One was a question posed on a dual listing which we were told is not on the cards at the moment but what they are looking at seriously is an US OTC listing following what other European companies are doing and reflects the fact that their shares undervalued in a US context. No timescale given. He was asked why no retail/Primary Bid offer in the recent equity raise. We did not get a clear answer but we were told that one thing they wanted to achieve was to balance out the shareholder register with the combined holdings of Ospraie and Griffiths over 50%. Both had agreed to stand aside in this fundraising and hopefully there will be more liquidity now in the shares. I applaud this but still not clear to me why there was no primary bid mechanism. He was asked why given that it was oversubscribed they did not raise more money. I did not get a very clear answer . We were told that they spend the cash very carefully but recognized that pretec investment is growing-my notes tell me $2.7m last year to a projected 2022 figure of $5m. I a m comfortable with the amount raised as it gives them enough for their identified requirements . I go on the basis that another fund raising may well be required in 18/24 months and touch wood the share price will be higher. He cautioned us not to expect big sales in Brazil soya this year. He said that the authorization from the Brazilian authorities came through faster than they had predicted so do not have all their ducks in a row.Their product is used to treat the seeds before planting ie in the August/October period depending on where they are in Brazil. Sales will thus be only a few months away and they have yet to finalize their discussions with potential distributor- at this stage looking to have 1 or 2 national ones. We were reminded that they do not have their manufacturing properly set up and will be using Penn State. Emphasized that when they are up and running they will not be doing their own manufacturing and are in discussions with 2 toll manufacturers. Where does this leave us? On the assumption that the US/£ FX rate is in the area of 1.35, I anticipate the share price in the 14/18 area for the near term. I think the key financial figures for 2020 have been well trailed so do not see the AR changing the price much. The mid year filing for authorization of 949 could provoke some movement and the interim figures hopefully will. Having the shares OTC in the US would move the dial.
22/3/2021
11:08
vsb234: Arden Partners says there is ‘significant value’ in Plant Health Care’s PREtec platform (www.voxmarkets.co.uk/articles/arden-partners-says-there-is-significant-value-in-plant-health-care-s-pretec-platform-a2d3732) New research from UK-based institute Arden Partners has highlighted the ‘significant value’ in Plant Health Care’s (PHC) technology platform, PREtec, within the global agriculture industry. PHC, which provides patent-protected biological products to global agricultural markets, announced its intention to raise up to US$10 million on Thursday through an oversubscribed placing at a price of 14p, a c.12% discount to its closing mid-market price on Wednesday. The funds will be used to accelerate the development of products from the PREtec platform, seek regulatory approval in Europe, support the expansion of the group’s commercial business which it said is ‘performing very well’, as well to strengthen PHC’s balance sheet. The group’s PREtec technology platform works by inducing natural defensive and metabolic responses in crop plants, helping to reduce harm from stresses during the growing season. To date, the company has invested more than US$20 million over the last eight years into its PREtech technology platform, with the first commercial product launch anticipated in 2H21. In a research note released yesterday, analysts at Arden said the group’s recent newflow indicates that its PREtec technology is continuing to gain traction, and with further funding now secured, ‘investors should focus on execution and growth across the Group’s portfolio.’ It said recent research on PREtec confirms ‘huge market opportunities for the products with demand built on robust, demonstrable efficacy and excellent sustainable credentials which align very well with the global ag industry’s current practices and overall direction of travel.’ It said its discussions with PHC’s distribution partners indicate excellent support for the products with many medium-term expansion opportunities built on patented technology. As a result of PHC’s recent positive newsflow, Arden has updated its earnings estimates in order to reflect the new equity and increased expenditure, as well as upgraded its medium-term revenue forecasts which it said reflects the added investment and expenditure. The research firm said it anticipates increased visibility through 2021 as the exact phasing and targeting of PHC’s resources takes shape. Meanwhile, it highlighted that the increased expenditure ‘should ultimately raise value creation in the medium term’ in its view. Shares in Plant Health Care have increased by nearly 30% since the beginning of 2021. The stock saw a strong start to the year after PH279 (now known and branded as Saori) became the first product from its PREtec platform to receive federal approval for sale in Brazil. Shares in the stock ticked up by 3.74% this morning to 18.31p following the fundraising. London-listed Plant Health Care is a leading provider of proprietary agricultural biological products and technology solutions focused on improving crop performance. Its commercial business is driven by sales of Harpin αß, a recombinant protein which acts as a powerful biostimulant, promoting the yield and quality of crops. PHC sells the proprietary soil treatment Myconate in selected countries and sells both Harpin αß and Myconate through specialist distributors globally. In Mexico, PHC distributes third-party biological products. PHC utilises its PREtec platform to generate numerous products and it is focusing on three products targeting very large market opportunities with a value of more than $5bn. The Group said these products are currently under evaluation with six potential commercial partners. Meanwhile, PHC also continues to evaluate further candidate products from its robust pipeline of development candidates for additional crops and indications. In a trading update released in January 2021, the Group reported robust in-market sales growth of Harpin αβ with in-market sales in Brazilfor sugarcane coming in at three times those of 2019, while in-market sales to corn came in at 1.8 times higher than the prior year. Meanwhile, the Group hailed its progress in bringing the first products from the PREtec platform to market. It highlighted it is planning for initial commercial launch in Brazil during the second half of 2021.
20/3/2021
22:00
cerrito: Thanks kenwright and I missed that. Very clear. Obvious by the shortness of his hair that he is not in the UK. I am surprised that it may be months before they announce their distributors in Brazil given that we are looking for an H2 launch. From what he inferred you use PHC 279 just after planting which in Brazil will be in November but may be I have got that wrong.
20/3/2021
21:14
kenwright: https://www.youtube.com/watch?v=GjjtARvusCo&t=2s PHC explanation for the fund raise
18/3/2021
18:53
cerrito: I have to say I did not see this fund raise coming and indeed I note that their cash out flow in H2 2020 reduced to USD1m. Irritated that there was no primary bid option but note that we were not offered this last time. Did not expect the share price to finish so strong. Congrats to those who bought first thing. A good deal of execution risk for the Brazil launch and not helped by the Covid situation. Btw, does anyone know if Richards based in UK or USA?
18/3/2021
17:11
dlem: Placing complete and more buying!!! PHC must have presented a compelling sales pitch.
01/3/2021
23:36
cerrito: share price reaction to the RNS understandable. In some ways I had taken these results for granted. The higher hurdle to jump is manufacturing and more important basic distribution and then key good old fashioned salesmanship.
27/5/2020
09:29
colin12345678: Highlights: US Corn - PHC 279 increased corn yields by 9-15% when applied as a foliar spray, creating potential grower value of $54 - $82 per acre at current average prices. - PHC279 significantly improved the control of two key corn diseases by as much as 50%, even under heavy disease pressure. Spring wheat - PHC279 increased yield by as much as 17% when added to the standard disease control program, which is worth $86 per acre at current prices. Lettuce - PHC279 increased yield by as much as 22% compared to fungicides alone. - PHC279 also improved disease control as much as 31% following foliar application. In the US, 91m acres of corn were planted in 2019. Severe southern rust disease can routinely reduce corn yields as much as 25 bushels per acre. At current prices, this would equate to lost revenue for the farmer of $79 per acre. In historical epidemics of southern corn leaf blight, yields were reduced by 20 to 25 percent nationwide, resulting in an estimated $1 billion loss in harvest. In the Company's trials, when PHC279 was applied together with a leading chemical fungicide, it significantly improved control of both diseases compared to the fungicide treatment alone, and yields were increased by as much as 26 bushels per acre depending on application timing. Even a more modest benefit of 5-10 bushels per acre is likely to provide an attractive return on investment in the potential range of 5:1 to 8:1 for farmers who apply PHC279 to their fields. In the UK, when PHC279 was applied to spring wheat seeds prior to planting, followed by adding it to the standard spray fungicide program, yield was increased by as much as 17% in fields with Septoria tritici blotch, the major disease of wheat in the UK. At current prices, this yield benefit would be worth $86 per acre to the farmer. Lettuce drop disease is a major pathogen affecting US lettuce cultivation. In a series of US field trials inoculated with Sclerotinia, the causative agent of lettuce drop disease, PHC279 treated plants yielded as much as 22% more than plants treated only with the standard chemical fungicide program. With an acre of lettuce worth more than $10,000 in the US in 2018, even a modest increase in lettuce yield will likely justify the cost of applying PHC279. Plant Health Care's PREtec peptides stimulate the plant to defend itself. Derived from natural proteins, this is a novel, environmentally friendly approach to protecting crops and increasing yields, compatible with mainstream agricultural practice. PHC279 may allow farmers to reduce applications of toxic fungicides or to achieve better control of disease. Gary L. Cloud, Ph.D., a research agronomist and owner of GLC Consulting, Inc. participated in the testing of PHC279 in corn this season, and offered the following, "There was heavy disease pressure and PHC279 provided visible improvement in disease control and higher yield compared to the standard fungicide when applied early in the growing season. That is somewhat amazing due to the time that elapsed between application and harvest. I believe PHC279 will be a valuable tool for corn growers struggling to control disease in their fields." Chris Richards, CEO of Plant Health Care, said "We are extremely encouraged with the performance of PHC279 in multiple key crops. Building on our recent success with PHC279 for the control of Asian soybean rust in Brazil, it is clear PHC279 will have important benefits for farmers in many crops. The registration of our first PREtec peptide is progressing in the US and Brazil and the scale-up of manufacturing has started. We are excited about the potential for products based on our PREtec peptides, which are targeting markets with an initial opportunity of $5 billion. We aim to launch the first peptides as soon as regulatory permits have been obtained, to offer these valuable new tools to growers in the US and other countries."
Plant Health Care share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
PHC
Plant Heal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210619 06:12:16